Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cancer trick the body into attacking its own platelets?

NCT ID NCT06444477

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 33 adults who had both immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — and cancer. Researchers wanted to see if treating the cancer could also improve ITP. They also investigated whether cancer cells might mimic platelets, triggering the immune attack. The goal is to better understand this connection and improve care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could clarify why some cancer patients develop low platelet counts and point toward better management strategies.
What could go wrong
This is a small, completed observational study (33 participants) with no intervention tested. Results may not apply to all cancer types or ITP patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

33 people

The number who actually took part.

Started

Aug 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a definite diagnosis of both ITP and cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with a definite diagnosis of both ITP and cancer; * Synchronous diagnosis of ITP and cancer; * Onset of ITP occurring 6 months before or after the diagnosis of cancer. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura cancer neoplasm Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Immune thrombocytopenia Immune thrombocytopenic purpura Neoplasms

Contacts and locations

Locations

  • AP-HM Hôpital la Timone - service de médecine interne

    Marseille, France

  • AP-HP Hôpital Bichat service de médecine interne

    Paris, France

  • AP-HP Hôpital Bicêtre service de médecine interne

    Le Kremlin-Bicêtre, France

  • AP-HP Hôpital Jean Verdier service de médecine interne

    Bondy, France

  • AP-HP Hôpital Mondor service de médecine interne

    Créteil, France

  • AP-HP Hôpital Saint-Antoine service de médecine interne

    Paris, France

  • AP-HP Hôpital Saint-Louis service immuno-hématologie

    Paris, France

  • CHRU d'Orléans - service de Médecine interne

    Orléans, France

  • CHRU d'Orléans - service de réanimation

    Orléans, France

  • CHRU de Nancy - service de Médecine Interne et Immunologie Clinique

    Nancy, France

  • CHRU de Strasbourg - service de médecine interne

    Strasbourg, France

  • CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses

    Pessac, France

  • CHU de Clermont-Ferrand - service de médecine interne

    Clermont-Ferrand, France

  • CHU de Lille - service d'Hématologie

    Lille, France

  • CHU de Montpellier - service d'Hématologie

    Montpellier, France

  • CHU de Nantes - service de médecine interne

    Nantes, France

  • CHU de Poitiers - service de médecine interne

    Poitiers, France

  • CHU de Toulouse - service de médecine interne

    Toulouse, France

  • CHU de Tours - service de médecine interne

    Tours, France

  • HCL - service d'Hématologie

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.